AEON Biopharma (NYSE: AEON) Q1 2026 loss, FDA boosts ABP-450 plan and debt cut
Rhea-AI Filing Summary
AEON Biopharma reported first-quarter 2026 results and a corporate update focused on its ABP-450 biosimilar program and balance sheet. The company recorded a net loss of $11.8 million for the quarter, compared with net income of $9.1 million in the prior-year period, largely driven by fair value changes in financial instruments.
Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development spending was $2.0 million. AEON ended March 31, 2026 with cash and cash equivalents of $6.2 million, and stated that, including $0.9 million of April ATM proceeds, this is expected to fund operations into the third quarter of 2026.
The company highlighted positive FDA feedback from a BPD Type 2a meeting supporting ABP-450’s analytical similarity strategy under the 351(k) biosimilar pathway. AEON also completed a $6 million PIPE financing and a Daewoong note exchange, which together reduced outstanding debt by more than 90% and contributed to shrinking total stockholders’ deficit from $(55.0) million to $(16.8) million.
Positive
- Debt reduction and capital raise: A $6 million PIPE financing and Daewoong note exchange reduced outstanding debt by more than 90%, easing balance sheet pressure and shrinking total stockholders’ deficit from $(55.0) million to $(16.8) million.
- Regulatory progress for ABP-450: Positive FDA BPD Type 2a feedback deemed AEON’s analytical plan reasonable under the 351(k) biosimilar pathway, clarifying the framework for its remaining analytical comparability work on ABP-450.
Negative
- Ongoing losses and short cash runway: AEON posted a Q1 2026 net loss of $11.8 million and, even including April ATM proceeds, expects existing cash to fund operations only into the third quarter of 2026.
- Stockholders’ deficit persists: Despite improvements, the company still reported total stockholders’ deficit of $(16.8) million at March 31, 2026, reflecting cumulative losses and reliance on external financing.
Insights
AEON advances ABP-450 with FDA feedback while extending but not resolving its tight cash runway.
AEON Biopharma is progressing ABP-450 under the 351(k) biosimilar pathway. Positive BPD Type 2a feedback suggests the FDA views its analytical plan as reasonable, a key step toward building the analytical similarity package needed for potential full-label biosimilar approval to BOTOX.
Financially, the company remains early-stage and loss-making. Q1 2026 net loss was $11.8 million, with higher research and development and selling, general and administrative expenses. Reported results are heavily influenced by non-cash fair value movements in convertible notes, warrants, and derivative liabilities, which can create volatility without matching cash effects.
Liquidity is tight: cash and cash equivalents were $6.2 million at March 31, 2026, and management expects, including $0.9 million of April ATM proceeds, to fund operations only into the third quarter of 2026. The $6 million PIPE and Daewoong note exchange have cut outstanding debt by more than 90% and reduced stockholders’ deficit, but additional financing will likely be important if development plans continue at the current pace.
8-K Event Classification
Key Figures
Key Terms
351(k) regulatory pathway regulatory
BPD Type 2a meeting regulatory
PIPE financing financial
warrant liabilities financial
derivative liability financial
analytical similarity technical
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol | | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On May 14, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the first quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).
The information furnished in this Item 2.02 of this Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.
Item 9.01. Financial Statement and Exhibits.
(d) Exhibits.
Exhibit No. | Description | ||||||||
99.1 | Press Release, dated May 14, 2026. | ||||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AEON Biopharma, Inc. | ||
Date: May 14, 2026 | By: | /s/ Robert Bancroft |
Robert Bancroft | ||
President and Chief Executive Officer | ||
Exhibit 99.1
PRESS RELEASE
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -
- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% -
- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -
IRVINE, Calif., May 14, 2026 – AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, reported today its financial results for the first quarter ended March 31, 2026, and provided a corporate update.
“During the first quarter, we made meaningful progress advancing the ABP-450 development program and strengthening the company’s financial position,” commented Rob Bancroft, President and Chief Executive Officer of AEON. “We believe feedback from our BPD Type 2a meeting with the FDA supports our analytical similarity strategy under the 351(k) pathway and provides greater clarity on the path forward. In addition, the completion of our recent financing transactions, including the exchange of Daewoong-held notes, significantly reduced our outstanding debt.”
“With this foundation in place, we are focused on executing our analytical program and preparing for our planned Type 2b interaction, where we will seek further feedback from the FDA on the full definition of program requirements. We believe this progress positions ABP-450 to advance efficiently toward potential full-label approval and our goal of introducing a new competitive dynamic in a large therapeutic category that has been long dominated by a single product.”
First Quarter 2026 Highlights and Recent Developments
Exhibit 99.1
PRESS RELEASE
| ● | Appointed John Bencich as Chief Financial Officer |
| o | Mr. Bencich joins AEON with more than 25 years of leadership experience spanning corporate strategy, capital market transactions, and business development across emerging growth and publicly traded companies. |
| ● | Presented Data and Advanced Scientific Engagement Supporting Analytical Similarity to BOTOX® |
| o | Chad Oh, M.D., AEON’s Chief Medical Officer, presented a poster at the 2026 American Academy of Neurology (AAN) Annual Meeting in April entitled “Establishing Primary Structure Comparability Between ABP-450 (prabotulinumtoxinA) and OnabotulinumtoxinA (Botox®) to Support Biosimilarity.” The poster expanded upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage. |
| o | An abstract was accepted for presentation at the upcoming American Headache Society (AHS) Annual Meeting on June 4-7, 2026 in Orlando, Florida entitled “Establishing Structural and Functional Comparability Between ABP-450 and OnabotulinumtoxinA to Support Biosimilarity.” The abstract will be presented on June 4th between 2:00 pm and 5:00 pm ET. |
Liquidity and Capital Resources
The Company reported cash and cash equivalents of $6.2 million as of March 31, 2026, which does not include the $0.9 million of proceeds received upon ATM financing in April 2026. Including those proceeds, cash and cash equivalents are expected to fund operations into the third quarter of 2026, supporting continued advancement of the ABP-450 program including ongoing analytical and regulatory activities.
Upcoming ABP-450 Development Milestones & Scientific and/or Corporate Events
| ● | June 4th-7th, 2026: Poster presentation at the 68th Annual Scientific Meeting of the American Headache Society. |
| ● | June 17th, 2026: Annual shareholder meeting being held at 10:00 AM PST in the Company’s offices at 5 Park Plaza, Suite 1750, Irvine, CA 92614. |
| ● | Second half 2026: BPD Type 2b meeting with the FDA to seek feedback on remaining biosimilar development plan, including pharmacodynamic and clinical program requirements. |
About the U.S. Biosimilar Pathway
Analytical similarity forms the scientific foundation of the 351(k) pathway and represents the most data-intensive phase of biosimilar development. When analytical comparability across critical quality attributes is robustly demonstrated, the FDA may reduce the scope of required clinical studies under its totality-of-the-evidence framework. Sponsors may also seek extrapolation to additional indications of the reference product when scientifically justified.
About AEON Biopharma
AEON Biopharma is a biopharmaceutical company pursuing full-label access to the U.S. therapeutic neurotoxin market via biosimilarity to BOTOXÒ. The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually, representing a major opportunity for biosimilar entry. ABP-450 is the same botulinum toxin complex currently approved and marketed for cosmetic indications by Evolus, Inc. under the name JeuveauÒ. ABP-450 is manufactured by Daewoong Pharmaceutical in a facility that has been authorized by the U.S. Food and Drug Administration, Health Canada, and European Medicines Agency for the manufacture of third-party botulinum toxin products. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. To learn more about AEON, visit www.aeonbiopharma.com.
Exhibit 99.1
PRESS RELEASE
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (i) AEON’s ability to continue to meet continued stock exchange listing standards; (ii) the Company’s ability to obtain additional and sufficient financing; (iii) the Company’s anticipated financial performance, including cash and cash equivalents; (iv) the Company’s plans regarding any interactions with the FDA; (v) the outcome of any regulatory interactions; and (vi) other risks and uncertainties set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s filings with the SEC, which are available on the SEC’s website at www.sec.gov.
Contacts
Investor Contact:
Hershel Berry
Blueprint Life Science Group
hberry@Bplifescience.com
Source: AEON Biopharma
Exhibit 99.1
AEON BIOPHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data and par value amounts)
| | March 31, | | | December 31, | ||
| | 2026 | | | 2025 | ||
| | | | | | ||
ASSETS | | | |
|
| | |
Current assets: | | | |
|
| | |
Cash and cash equivalents | | $ | 6,243 | | | $ | 3,006 |
Prepaid expenses and other current assets | |
| 382 | | |
| 392 |
Total current assets | |
| 6,625 | | |
| 3,398 |
Property and equipment, net | |
| 142 | | |
| 162 |
Operating lease right-of-use asset | |
| 992 | | |
| 1,052 |
Other assets | |
| 871 | | |
| 948 |
Total assets | | $ | 8,630 | | | $ | 5,560 |
LIABILITIES AND STOCKHOLDERS' DEFICIT | |
| | | |
| |
Current liabilities: | |
| | | |
| |
Accounts payable | | $ | 1,481 | | | $ | 942 |
Accrued clinical trials expenses | |
| 1,173 | | |
| 1,426 |
Accrued compensation | |
| 1,832 | | |
| 2,872 |
Other accrued expenses | |
| 2,183 | | |
| 1,657 |
Total current liabilities | |
| 6,669 | | |
| 6,897 |
Convertible notes at fair value, including related party amount of $1,542 and $34,600, at March 31, 2026 and December 31, 2025, respectively | |
| 1,542 | | |
| 34,600 |
Operating lease liability | |
| 825 | | |
| 893 |
Derivative liability | | | — | | | | 14,879 |
Warrant liabilities | | | 16,308 | | | | 3,276 |
Contingent consideration liability | | | 38 | | | | 42 |
Total liabilities | |
| 25,382 | | |
| 60,587 |
Commitments and contingencies | |
| | | |
| |
Stockholders’ Deficit: | |
| | | |
| |
Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at March 31, 2026 and December 31, 2025, respectively, and 25,303,058 and 12,105,902 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | |
| 10 | | |
| 9 |
Additional paid-in capital | |
| 465,850 | | |
| 415,783 |
Accumulated deficit | |
| (482,612) | | |
| (470,819) |
Total stockholders' deficit | |
| (16,752) | | |
| (55,027) |
Total liabilities and stockholders' deficit | | $ | 8,630 | | | $ | 5,560 |
Exhibit 99.1
PRESS RELEASE
AEON BIOPHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(in thousands, except share and per share data)
| | | | | | |
| | March 31, | ||||
| | 2026 | | 2025 | ||
Operating expenses: |
| | |
| | |
Selling, general and administrative | | $ | 3,903 | | $ | 3,125 |
Research and development | |
| 2,034 | |
| 825 |
Change in fair value of contingent consideration | |
| (4) | |
| (3,488) |
Total operating costs and expenses | |
| 5,933 | |
| 462 |
Loss from operations | |
| (5,933) | |
| (462) |
Other (loss) income: | |
| | |
| |
Change in fair value of convertible notes | |
| (8,727) | |
| (1,631) |
Change in fair value of warrants | |
| 4,656 | |
| 86,729 |
Loss on issuance of warrants | | | — | | | (75,644) |
Loss on extinguishment of debt | | | (76) | | | — |
Loss on derivative liability | | | (1,743) | | | — |
Other income, net | |
| 30 | |
| 103 |
Total other loss, net | |
| (5,860) | |
| 9,557 |
(Loss) income before taxes | |
| (11,793) | |
| 9,095 |
Income taxes | |
| — | |
| — |
Net (loss) income | | $ | (11,793) | | $ | 9,095 |
Basic net (loss) income per share | | $ | (0.29) | | $ | 2.28 |
Weighted average shares of common stock outstanding used to compute basic and diluted net (loss) income per share | | | 40,614,087 | | | 3,984,876 |
The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The condensed consolidated financial statements include the accounts of the Company and its controlled subsidiaries.
# # #
FAQ
How did AEON (AEON) perform financially in Q1 2026?
AEON reported a net loss of $11.8 million for Q1 2026. Operating expenses were driven by $3.9 million in selling, general and administrative costs and $2.0 million in research and development, reflecting continued investment in the ABP-450 biosimilar program.
What is AEON Biopharma’s cash runway after Q1 2026?
AEON ended March 31, 2026 with $6.2 million in cash and cash equivalents. Including an additional $0.9 million raised via ATM financing in April 2026, management expects this liquidity to fund operations into the third quarter of 2026.
How did AEON Biopharma strengthen its balance sheet in early 2026?
The company completed a $6 million PIPE financing and exchanged convertible notes held by Daewoong Pharmaceutical. Together, these transactions reduced outstanding debt by more than 90% and significantly narrowed the total stockholders’ deficit compared with December 31, 2025.
What regulatory progress did AEON report for ABP-450 as a biosimilar to BOTOX?
AEON reported positive feedback from an FDA BPD Type 2a meeting. The Agency considered its analytical similarity strategy for ABP-450 under the 351(k) biosimilar pathway reasonable, helping define the framework for completing its analytical comparability program.
What were AEON Biopharma’s key balance sheet figures at March 31, 2026?
Total assets were $8.6 million, while total liabilities were $25.4 million, resulting in total stockholders’ deficit of $(16.8) million. Warrant liabilities were $16.3 million, and convertible notes at fair value totaled $1.5 million after the Daewoong note exchange.
How did non-cash items affect AEON’s Q1 2026 results?
Results were significantly influenced by fair value changes in financial instruments. The company recorded a $8.7 million loss on convertible notes, a $4.7 million gain on warrants, and a $1.7 million loss on derivative liability, impacting reported net loss.